{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:06:11Z","timestamp":1787731571479,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CZ.02.2.69\/0.0\/0.0\/19_073\/0016713 DSGC-2021-0143"],"award-info":[{"award-number":["CZ.02.2.69\/0.0\/0.0\/19_073\/0016713 DSGC-2021-0143"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["DRO FNOL 00098892"],"award-info":[{"award-number":["DRO FNOL 00098892"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NU20-03-00201"],"award-info":[{"award-number":["NU20-03-00201"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Palacky University Olomouc","doi-asserted-by":"publisher","award":["LF_2024_004"],"award-info":[{"award-number":["LF_2024_004"]}],"id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Palacky University Olomouc","doi-asserted-by":"publisher","award":["LF_2024_010"],"award-info":[{"award-number":["LF_2024_010"]}],"id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jmoldx.2025.02.006","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T20:23:17Z","timestamp":1742847797000},"page":"446-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Platelets, Chromogranin A, and C-Reactive Protein Predict Therapy Failure of Metastatic Hormone-Sensitive Prostate Cancer while miR-375 Outperforms Prostate-Specific Antigen in Stratifying Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7765-4016","authenticated-orcid":false,"given":"Eva","family":"Chrenkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"Spurn\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina","family":"Hol\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Vrbkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Knillov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Levkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"\u0160tudentov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4842-1720","authenticated-orcid":false,"given":"Jan","family":"Bouchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2025.02.006_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/0008-5472.CAN-15-3172","article-title":"Commentary on Huggins and Hodges: \u201cStudies on prostatic cancer.\u201d","volume":"76","author":"Nelson","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib4","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"ENZAMET trial investigators and the Australian and New Zealand urogenital and prostate cancer trials group: enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"ARASENS trial investigators: darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib7","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib8","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/pros.23804","article-title":"Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide","volume":"79","author":"Lolli","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12082139","article-title":"Multiplex digital PCR to detect amplifications of specific androgen receptor loci in cell-free DNA for prognosis of metastatic castration-resistant prostate cancer","volume":"12","author":"Du","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/jcm11010257","article-title":"Biomarkers of castrate resistance in prostate cancer: androgen receptor amplification and T877A mutation detection by multiplex droplet digital PCR","volume":"11","author":"Young","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41391-018-0043-z","article-title":"Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients","volume":"21","author":"Kohli","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/medicina58040529","article-title":"Diagnostic value of microRNA-375 as future biomarker for prostate cancer detection: a meta-analysis","volume":"58","author":"Nitusca","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/clinchem\/hvaa095","article-title":"Prognostic value of novel liquid biomarkers in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: a prospective observational study","volume":"66","author":"Benoist","year":"2020","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1394292","article-title":"Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers","volume":"14","author":"Chrenkova","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/pcan.2011.60","article-title":"Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow inflammation outcome study","volume":"15","author":"Shafique","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41391-020-0209-3","article-title":"Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis","volume":"23","author":"Guan","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","article-title":"On the exact distribution of maximally selected rank statistics","volume":"43","author":"Hothorn","year":"2003","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v094.i04","article-title":"Bess: an R package for best subset selection in linear, logistic and cox proportional hazards models","volume":"94","author":"Wen","year":"2020","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/1878-0261.12185","article-title":"Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells","volume":"12","author":"Feiersinger","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/pros.23741","article-title":"Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram","volume":"79","author":"Majera","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib24","first-page":"00101","article-title":"Radiographic progression without corresponding prostate-specific antigen progression in patients with metastatic castration-sensitive prostate cancer receiving apalutamide: secondary analysis of the TITAN trial","volume":"S2588-9311","author":"Fukuokaya","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s12253-016-0171-5","article-title":"Serum chromogranin A as a complementary marker for the prediction of prostate cancer-specific survival","volume":"23","author":"Niedworok","year":"2017","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib26","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.2147\/CMAR.S190678","article-title":"Chromogranin A is a predictor of prognosis in patients with prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Guo","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib27","article-title":"Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel\/prednisone with or without bevacizumab","author":"Nixon","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bju.15647","article-title":"Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis","volume":"130","author":"Kannan","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pros.23465","article-title":"Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients","volume":"78","author":"Fan","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib30","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s10147-020-01712-y","article-title":"Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer","volume":"25","author":"Fukuokaya","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib31","first-page":"803","article-title":"Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide","volume":"73","author":"Pisano","year":"2021","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib32","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1038\/s41467-024-47516-w","article-title":"Platelets favor the outgrowth of established metastases","volume":"15","author":"Garcia-Leon","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib33","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/bjc.2014.13","article-title":"Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer","volume":"110","author":"Merson","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.868031","article-title":"Prognostic and predictive value of liquid biopsy-derived androgen receptor variant 7 (AR-V7) in prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Khan","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib36","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-22-0140","article-title":"Androgen receptor mutations for precision medicine in prostate cancer","volume":"29","author":"Shiota","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib37","first-page":"4030","article-title":"Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant","volume":"9","author":"Sumiyoshi","year":"2019","journal-title":"Prostate Cancer Sci Rep"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41598-019-57101-7","article-title":"Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer","volume":"10","author":"Zedan","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib39","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fonc.2019.00900","article-title":"Circulating MicroRNAs as biomarkers for prostate cancer detection and metastasis development prediction","volume":"9","author":"Bidarra","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/15579883241234747","article-title":"Prognostic value of lymphocyte-to-monocyte ratio (LMR) in patients with prostate cancer: a systematic review and meta-analysis","volume":"18","author":"Xiang","year":"2024","journal-title":"Am J Mens Health"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000446098","article-title":"C-reactive protein is a prognostic marker for patients with castration-resistant prostate cancer","volume":"39","author":"Liao","year":"2016","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib42","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s13277-014-2670-x","article-title":"Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients","volume":"36","author":"Xu","year":"2015","journal-title":"Tumor Biol"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib43","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients","volume":"6","author":"Gu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmoldx.2025.02.006_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33774-4","article-title":"Plasma androgen receptor and serum chromogranin A in advanced prostate cancer","volume":"8","author":"Conteduca","year":"2018","journal-title":"Sci Rep"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157825000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157825000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:43:51Z","timestamp":1762548231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157825000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525157825000637"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2025.02.006","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelets, Chromogranin A, and C-Reactive Protein Predict Therapy Failure of Metastatic Hormone-Sensitive Prostate Cancer while miR-375 Outperforms Prostate-Specific Antigen in Stratifying Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2025.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}